大麻二酚在难治性癫痫中起什么作用？

What is the role of cannabidiol in refractory epilepsy?

作者信息

LaFleur Kathryn M, Nemec Eric C

机构信息

At the time this article was written, Kathryn M. LaFleur was a student in the PA program at Sacred Heart University in Fairfield, Conn. Eric C. Nemec II is director of research and assessment and a clinical associate professor in the PA program at Sacred Heart University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

出版信息

JAAPA. 2019 Mar;32(3):16-18. doi: 10.1097/01.JAA.0000553393.36249.df.

DOI:10.1097/01.JAA.0000553393.36249.df

PMID:30817475

Abstract

The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.

摘要

美国食品药品监督管理局（FDA）最近批准了首款用于治疗患有德雷维特综合征和伦诺克斯-加斯东综合征患者的难治性癫痫的大麻二酚口服药物。本文描述了大麻二酚治疗难治性癫痫患者的安全性和有效性。